Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
eOD-GT8 60mer
- Development stage
- Unknown
- Lead developer
- International AIDS Vaccine Initiative
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
eOD-GT8 60mer is an experimental HIV-1 vaccine candidate designed using a germline-targeting strategy. Developed by the International AIDS Vaccine Initiative (IAVI) in collaboration with Scripps Research, it consists of an engineered outer domain (eOD) of the HIV-1 gp120 protein. This immunogen is specifically designed to have high affinity for the germline precursors of VRC01-class broadly neutralizing antibodies (bnAbs). The eOD is linked to a lumazine synthase (LumSyn) protein, which self-assembles into a 60-mer icosahedral nanoparticle to enhance immune recognition. In clinical trials, it is typically administered with the AS01B adjuvant. The primary goal of the vaccine is to prime rare B cell precursors that can eventually be matured into bnAbs through subsequent booster immunizations to prevent HIV infection.
- Other names
- eOD-GT8 60-mereOD-GT-8 60-mereOD-GT 8 60-mereOD-GT8eOD-GT-8eOD-GT 8engineered outer domain germline targeting version 8 60mer
Beyond the preview
Go deeper on eOD-GT8 60mer.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on eOD-GT8 60mer.